|
|
Article: Despite Technical Hurdles, Potential to Transform Drug Discovery and Development to Drive Gene Expression Markets.
- Article from:
- PR Newswire Europe
- Article date:
- November 20, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
LONDON, November 20 /PRNewswire/ -- The analysis of gene sequence and gene expression variations allows for the detection of defective genes and polymorphisms associated with specific diseases. These techniques provide the initial answers as to whether a potential therapeutic compound merits further evaluation and testing, making it of immense use to drug discovery and development. Despite its considerable benefits, however, gene expression still faces continued hurdles.
Frost & Sullivan (http://www.healthcare.frost.com) finds that Gene Expression Markets in Europe earned revenues of US$405.6 million in 2005 and estimates this to reach US$1.9 billion in 2012.